Back to top
more

TESARO, Inc. (TSRO)

(Delayed Data from NSDQ)

$74.96 USD

74.96
NA

0.00 (0.00%)

Updated Jan 18, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2

by Zacks Equity Research

TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.

    Tesaro (TSRO) Reports Q2 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Tesaro (TSRO) delivered earnings and revenue surprises of -14.29% and -11.29%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

      by Zacks Equity Research

      Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.

        AstraZeneca/Merck's Lynparza Betters Survival in Phase III

        by Zacks Equity Research

        AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.

          Implied Volatility Surging for Tesaro (TSRO) Stock Options

          by Zacks Equity Research

          Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately.

            TESARO (TSRO) Stock Up on Rumors of Buyout Offer From Roche

            by Zacks Equity Research

            Shares of TESARO (TSRO) rise on speculation of an acquisition bid from Roche.

              Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?

              by Zacks Equity Research

              Roche (RHHBY) is looking to boost its portfolio with some strategic acquisitions and we expect further activities on this front.

                TESARO Collaborates With Roche to Develop Zejula Combination

                by Zacks Equity Research

                TESARO (TSRO) collaborates with Genentech, a subsidiary of Roche, to develop Zejula in combination with an immune-oncology drug for treating ovarian cancer.

                  Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer

                  by Zacks Equity Research

                  Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.

                    Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat

                    by Zacks Equity Research

                    Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.

                      Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy

                      by Zacks Equity Research

                      Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.

                        Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug

                        by Zacks Equity Research

                        Clovis' (CLVS) ovarian cancer drug, Rubraca, gets positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                          Is the Options Market Predicting a Spike in TESARO (TSRO) Stock?

                          by Zacks Equity Research

                          Investors in TESARO (TSRO) need to pay close attention to the stock based on moves in the options market lately.

                            Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss

                            by Zacks Equity Research

                            Clovis (CLVS) witnesses narrower year-over-year loss in the fourth quarter. However, the company's revenues miss estimates. Rubraca sales lower.

                              AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan

                              by Zacks Equity Research

                              AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.

                                Clovis Up More Than 50% in 2017: What's Driving the Stock?

                                by Zacks Equity Research

                                Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.

                                  Clovis' sNDA for Rubraca Gets Priority Review in the U.S.

                                  by Zacks Equity Research

                                  The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.

                                    TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU

                                    by Zacks Equity Research

                                    TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.

                                      Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

                                      by Zacks Equity Research

                                      Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

                                        AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

                                        by Zacks Equity Research

                                        AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

                                          Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca

                                          by Zacks Equity Research

                                          Clovis submitted a sNDA to the FDA for expansion of Rubraca's label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.

                                            Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?

                                            by Zacks Equity Research

                                            Investors in Tesaro (TSRO) need to pay close attention to the stock based on moves in the options market lately.

                                              The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

                                              by Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

                                                Arpita Dutt headshot

                                                3 Biotech and Pharma Stocks with Key FDA Catalysts this October

                                                by Arpita Dutt

                                                Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.

                                                  Cancer Space Update: Mixed Week for Pfizer, Roche Falters

                                                  by Zacks Equity Research

                                                  Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.